196 related articles for article (PubMed ID: 12488511)
1. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo.
Coleman JE; Huentelman MJ; Kasparov S; Metcalfe BL; Paton JF; Katovich MJ; Semple-Rowland SL; Raizada MK
Physiol Genomics; 2003 Feb; 12(3):221-8. PubMed ID: 12488511
[TBL] [Abstract][Full Text] [Related]
2. Production of lentiviral vectors for transducing cells from the central nervous system.
Li M; Husic N; Lin Y; Snider BJ
J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
[TBL] [Abstract][Full Text] [Related]
3. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
4. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods.
Sastry L; Johnson T; Hobson MJ; Smucker B; Cornetta K
Gene Ther; 2002 Sep; 9(17):1155-62. PubMed ID: 12170379
[TBL] [Abstract][Full Text] [Related]
5. Viral gene delivery: optimized protocol for production of high titer lentiviral vectors.
Hewinson J; Paton JF; Kasparov S
Methods Mol Biol; 2013; 998():65-75. PubMed ID: 23529421
[TBL] [Abstract][Full Text] [Related]
6. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.
Pacchia AL; Adelson ME; Kaul M; Ron Y; Dougherty JP
Virology; 2001 Mar; 282(1):77-86. PubMed ID: 11259192
[TBL] [Abstract][Full Text] [Related]
7. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes.
Sakoda T; Kasahara N; Hamamori Y; Kedes L
J Mol Cell Cardiol; 1999 Nov; 31(11):2037-47. PubMed ID: 10591030
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo.
Zhao J; Pettigrew GJ; Thomas J; Vandenberg JI; Delriviere L; Bolton EM; Carmichael A; Martin JL; Marber MS; Lever AM
Basic Res Cardiol; 2002 Sep; 97(5):348-58. PubMed ID: 12200634
[TBL] [Abstract][Full Text] [Related]
9. Self-inactivating lentiviral vectors with U3 and U5 modifications.
Iwakuma T; Cui Y; Chang LJ
Virology; 1999 Aug; 261(1):120-32. PubMed ID: 10441560
[TBL] [Abstract][Full Text] [Related]
10. Optimized large-scale production of high titer lentivirus vector pseudotypes.
Sena-Esteves M; Tebbets JC; Steffens S; Crombleholme T; Flake AW
J Virol Methods; 2004 Dec; 122(2):131-9. PubMed ID: 15542136
[TBL] [Abstract][Full Text] [Related]
11. Generation of lentivirus vectors using recombinant baculoviruses.
Lesch HP; Turpeinen S; Niskanen EA; Mähönen AJ; Airenne KJ; Ylä-Herttuala S
Gene Ther; 2008 Sep; 15(18):1280-6. PubMed ID: 18463689
[TBL] [Abstract][Full Text] [Related]
12. Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins.
Trabalza A; Eleftheriadou I; Sgourou A; Liao TY; Patsali P; Lee H; Mazarakis ND
J Virol; 2014 Mar; 88(5):2877-90. PubMed ID: 24371049
[TBL] [Abstract][Full Text] [Related]
13. Improved third-generation lentiviral packaging with pLKO.1C vectors.
Lee S; Cobrinik D
Biotechniques; 2020 Jun; 68(6):349-352. PubMed ID: 32141762
[TBL] [Abstract][Full Text] [Related]
14. Generation of a genome scale lentiviral vector library for EF1α promoter-driven expression of human ORFs and identification of human genes affecting viral titer.
Škalamera D; Dahmer M; Purdon AS; Wilson BM; Ranall MV; Blumenthal A; Gabrielli B; Gonda TJ
PLoS One; 2012; 7(12):e51733. PubMed ID: 23251614
[TBL] [Abstract][Full Text] [Related]
15. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors.
Xu K; Ma H; McCown TJ; Verma IM; Kafri T
Mol Ther; 2001 Jan; 3(1):97-104. PubMed ID: 11162316
[TBL] [Abstract][Full Text] [Related]
16. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors.
Haas DL; Case SS; Crooks GM; Kohn DB
Mol Ther; 2000 Jul; 2(1):71-80. PubMed ID: 10899830
[TBL] [Abstract][Full Text] [Related]
17. [Transduction of recombinant marrow stem cells using lentiviral vector and adenoviral vector: a comparative study].
Ma XS; Jiang JY; Lü FZ; Ma X; Li XK; Huang HY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(47):3340-4. PubMed ID: 17313830
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing the titer and infectivity of lentiviral vectors.
Logan AC; Nightingale SJ; Haas DL; Cho GJ; Pepper KA; Kohn DB
Hum Gene Ther; 2004 Oct; 15(10):976-88. PubMed ID: 15585113
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment.
Sastry L; Xu Y; Cooper R; Pollok K; Cornetta K
Hum Gene Ther; 2004 Feb; 15(2):221-6. PubMed ID: 14975194
[TBL] [Abstract][Full Text] [Related]
20. Large-scale production of pseudotyped lentiviral vectors using baculovirus GP64.
Kumar M; Bradow BP; Zimmerberg J
Hum Gene Ther; 2003 Jan; 14(1):67-77. PubMed ID: 12573060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
